| Oct 31 |
Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
|
| Oct 22 |
MangoRx Announces Formation of Strategy and Alternatives Committee
|
| Oct 21 |
Mangoceuticals refutes claims made by Lilly in weight-loss drug lawsuit
|
| Oct 21 |
MangoRx Responds to and Refutes Recent Claims Made by Eli Lilly
|
| Oct 18 |
Mangoceuticals, Inc. Announces Participation at the Centurion One Capital 2nd Annual Bahamas Summit 2024
|
| Oct 11 |
Mangoceuticals announces 1-for-15 reverse stock split
|
| Oct 11 |
MANGOCEUTICALS, INC. ANNOUNCES 1-FOR 15 REVERSE STOCK SPLIT AS PART OF NASDAQ COMPLIANCE PLAN
|
| Oct 3 |
MangoRx Introduces Oral Tirzepatide GLP-1 Receptor Agonist for Advanced Weight Loss Solutions
|
| Oct 1 |
MangoRx Addresses $49.3 Billion Global GLP-1 Market With Launch of Oral Semaglutide for Advanced Weight Loss Treatment
|
| Aug 17 |
Mangoceuticals Second Quarter 2024 Earnings: US$0.092 loss per share (vs US$0.14 loss in 2Q 2023)
|
